Intravenous Immunoglobulin therapy for anti-E hemolytic disease in the newborn.
Anti-E alloimmunisation is a less common cause of haemolytic disease in the newborn (HDN) and is usually associated with mild to moderate clinical manifestations, that are often less severe than anti-D immunisation. Conventional treatments for HDN are phototherapy and exchange transfusion, the latter still representing a high-risk procedure. Currently, intravenous immunoglobulin has been used as alternative treatment for HDN to reduce the need for exchange transfusion, as well as the length of phototherapy and hospitalisation. We report a case of anti-E HDN treated successfully with intravenous immunoglobulin, as adjuvant treatment to phototherapy.
Onesimo
Roberta
R
Department of Pediatric Sciences, Catholic University, Gemelli Hospital, Rome, Italy.
Rizzo
Daniela
D
Ruggiero
Antonio
A
Valentini
Piero
P
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004899:Erythroblastosis, Fetal / Q000628:therapy*; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007231:Infant, Newborn; D010789:Phototherapy; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System / Q000276:immunology
D000276:Adjuvants, Immunologic; D016756:Immunoglobulins, Intravenous; D012204:Rh-Hr Blood-Group System